Evolution of multiple myeloma treatment from melphalan
monotherapy to bone marrow transplantation

J 1996

Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation

HÁJEK, Roman, Zdeněk ADAM, I. VÁŠOVÁ a Z. KRÁL

Základní údaje

Originální název

Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation

Název česky

Vývoj léčby mnohočetného myelomu od monoterapie melfalanem k transplantaci kostní dřeně

Autoři

HÁJEK, Roman (203 Česká republika, garant), Zdeněk ADAM (203 Česká republika), I. VÁŠOVÁ (203 Česká republika) a Z. KRÁL (203 Česká republika)

Vydání

Acta medica Austriaca, Austria, Springer Verlag, 1996, 0303-8173

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Lékařská fakulta

UT WoS

A1996VF28300001

Klíčová slova česky

mnohočetný myelom; melphalan

Klíčová slova anglicky

multiple myeloma; melphalan

Štítky

melphalan, multiple myeloma

Změněno: 24. 6. 2009 08:25, Mgr. Anna Potáčová, Ph.D.

Anotace

ORIG CZ

V originále

Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. The median of survival was prolonged from several months to 3 years. In the following 3 decades new drugs were tested, but no other drug brought better results than melphalan. The comparative studies have proved, that therapy response has been reached more rapidly after polychemotherapy than after monotherapy, but none of the treatment modalities differed in the survival parameters. The significance of interferon alpha for the treatment of multiple myeloma has been tested since the beginning of the eighties. Many clinical trials have brought controversial results. The latest metaanalysis and data published support the indication of interferon alpha for the multiple myeloma maintenance treatment. Important progress in the therapy of multiple myeloma has been done in the nineties. High doses of alkylating cytostatics with the support of autologous peripheral blood stem cells transplantation or bone marrow transplantation enhanced the number of therapy-responses and prolonged the survival. The results of autologous transplantations are so favourable, that this procedure can be recommended as the first line treatment in suitable patients. Allogenic bone marrow transplantation is linked with many complications and therefore this method will be performed only in a limited number of patients. Trials dealing with this new therapy-trends are viewed in this paper.

Česky

V publikaci je podán přehled o vývoji léčby mnohočetného myelomu.

Citovat

HÁJEK, Roman, Zdeněk ADAM, I. VÁŠOVÁ a Z. KRÁL. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Acta medica Austriaca. Austria: Springer Verlag, 1996, roč. 23, č. 3, s. 85-91. ISSN 0303-8173.

@article{838157,
   author = {Hájek, Roman and Adam, Zdeněk and Vášová, I. and Král, Z.},
   article_location = {Austria},
   article_number = {3},
   keywords = {multiple myeloma; melphalan},
   language = {eng},
   issn = {0303-8173},
   journal = {Acta medica Austriaca},
   title = {Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation},
   volume = {23},
   year = {1996}
}

TY  - JOUR
ID  - 838157
AU  - Hájek, Roman - Adam, Zdeněk - Vášová, I. - Král, Z.
PY  - 1996
TI  - Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation
JF  - Acta medica Austriaca
VL  - 23
IS  - 3
SP  - 85-91
EP  - 85-91
PB  - Springer Verlag
SN  - 03038173
KW  - multiple myeloma
KW  - melphalan
N2  - Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. The median of survival was prolonged from several months to 3 years. In the following 3 decades new drugs were tested, but no other drug brought better results than melphalan. The comparative studies have proved, that therapy response has been reached more rapidly after polychemotherapy than after monotherapy, but none of the treatment modalities differed in the survival parameters. The significance of interferon alpha for the treatment of multiple myeloma has been tested since the beginning of the eighties. Many clinical trials have brought controversial results. The latest metaanalysis and data published support the indication of interferon alpha for the multiple myeloma maintenance treatment. Important progress in the therapy of multiple myeloma has been done in the nineties. High doses of alkylating cytostatics with the support of autologous peripheral blood stem cells transplantation or bone marrow transplantation enhanced the number of therapy-responses and prolonged the survival. The results of autologous transplantations are so favourable, that this procedure can be recommended as the first line treatment in suitable patients. Allogenic bone marrow transplantation is linked with many complications and therefore this method will be performed only in a limited number of patients. Trials dealing with this new therapy-trends are viewed in this paper.
ER  -

HÁJEK, Roman, Zdeněk ADAM, I. VÁŠOVÁ a Z. KRÁL. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. \textit{Acta medica Austriaca}. Austria: Springer Verlag, 1996, roč.~23, č.~3, s.~85-91. ISSN~0303-8173.

Podrobný výpis o publikaci